COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

ICCVAM Logo

ICCVAM Biennial Report 2018-2019

ICCVAM Biennial Report 2018-2019
Menu
https://ntp.niehs.nih.gov/go/892673

Retrofitting Existing Tox21 HTS Assays with Metabolic Capability

The HTS assays that have been run in the Tox21 testing program to date generally lack the metabolic activity found in living systems, which can potentially increase or decrease the toxicity of chemicals. As a result, HTS results may not accurately reflect in vivo activity. Scientists at EPA, NCATS, and NIEHS are using several approaches to address this problem: adding human or rat liver microsomes into the existing assays, transfecting cells with mRNAs encoding human metabolic enzymes, or using metabolically capable human HepaRG cells. The addition of metabolic capacity to HTS assays is expected to improve characterization of the in vivo activity of chemicals in the Tox21 collection. Current efforts focus on retrofitting three types of assays for which a massive amount of data have already been generated: cellular stress-related assays, endocrine disruption assays, and CYP450 enzyme inhibition assays. The retrofitted assays are being used to screen the Tox21 10K chemical library to identify chemicals that are either bioactivated or detoxified by metabolic activity.

"Performance-based Validation of Tox21 ..." - previous article
next article - "Expansion of Pathway Coverage ..."
Tags: